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To the Editor: I have read with great interest the new edition of ACG guidelines on 
Crohn disease (CD) (1). Most of the statements are immediately applicable not only 
in the United States, but also in Europe. 
There are however some small but important differences in the management of these 
patients in Europe. 
Regarding the diagnostic methods, the authors focused mainly on Computed 
tomography enterography (CTE) and magnetic resonance enterography (MRE). In 
Europe bowel ultrasonography is a widely used diagnostic method that has shown to 
have a comparable diagnostic accuracy, with a lower cost and no radiation emission 
(the latter feature compared to CTE) (2). If bowel ultrasonography is not widespread 
in the USA, it would be interesting to know why. 
Regarding the factors that can influence the course of the disease, the authors 
concluded that there are no studies on CD concerning the use of selective 
cyclooxygenase-2 inhibitors (Coxibs) and that in a short-term therapy they have not 
shown to cause exacerbation of ulcerative colitis. An European meta-analysis found 
that gastrointestinal symptoms appear in most cases after a few days of use of 
Coxibs, and that the risk of worsening intestinal symptoms can occur mainly in 
patients with an active intestinal disease (3). Therefore, a possible strategy could be 
a careful follow-up of patients with inactive IBD during the first few days of treatment 
with Coxibs, due to a possible intestinal relapse, but in patients with a good tolerance 
in the first two weeks, a long- term therapy could be feasible (up to three months). 
Finally, the authors have dedicated a paragraph to biosimilar anti-TNF agents. They 
have mentioned a randomized, non-inferiority phase 4 research on patients affected 
by CD, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and 
plaque psoriasis showing that switching from infliximab originator to CT-P13 
(biosimilar) was not worsening the course of the disease more than continuing with 
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the originator (4). A letter from Europe commenting on the research emphasized that 
the results on CD itself are emblematic of the statistical problems associated with this 
study: among the 175 patients with CD, the risk of disease worsening was –14.3%, 
close to the 15% non-inferiority margin, and the risk would have exceeded 15% if the 
results of the most rigorous intention-to-treat statistical analysis had been reported 
instead of the per-protocol analysis (5). Furthermore, the authors (4) themselves 
pointed out that the study did not have sufficient statistical power to show non-
inferiority in individual pathologies (i.e. CD). It would be interesting to know more 
comments on a hot topic like that of the efficacy of biosimilars. 
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